u American Biogenetic Sciences Inc., of Copiague, N.Y., has signed aclinical trial agreement with New England Deaconess Hospital andHarvard Medical School in Boston to study the company's solublefibrin diagnostic test, SOLFIB, for blood clot formation. SOLFIB is anenzyme immunoassay using monoclonal antibodies, which have anaffinity for fibrin polymer, to detect an impending heart attack or toscreen post-operatively for clot formation.u GeneMedicine Inc., of Houston, has received a $75,000 Phase I SmallBusiness Innovation Research Grant from the National Institutes ofHealth to help fund development of the company's gene-switchtechnology, which is designed to control gene function by using steroiddrugs.081894

(c) 1997 American Health Consultants. All rights reserved.